Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab
| Autor: | Rhona Stein, Hans J. Hansen, David M. Goldenberg, Dave S. Solis, Zhengxing Qu, Susan Chen |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Cytotoxicity
Immunologic Lymphoma B-Cell Lymphoma medicine.drug_class Immunology Transplantation Heterologous Apoptosis Mice SCID Biology Humanized antibody Monoclonal antibody Antibodies Monoclonal Humanized Biochemistry Immunoglobulin G Antibodies Monoclonal Murine-Derived Mice Cell Line Tumor medicine Animals Humans Cell Proliferation Antibody-dependent cell-mediated cytotoxicity Neoplasia Effector Antibody-Dependent Cell Cytotoxicity Antibodies Monoclonal Cell Biology Hematology Complement System Proteins HLA-DR Antigens Fragment crystallizable region Burkitt Lymphoma Monoclonal biology.protein Female Antibody Rituximab Neoplasm Transplantation |
| Zdroj: | Blood. 108(8) |
| ISSN: | 0006-4971 |
| Popis: | HLA-DR is under investigation as a target for monoclonal antibody (mAb) therapy of malignancies. Here we describe a humanized IgG4 form of the anti-HLA-DR mAb L243, hL243γ4P (IMMU-114), generated to provide an agent with selectivity toward neoplastic cells that can kill without complement-dependent cytotoxicity (CDC) or antibody-dependent cellular-cytotoxicity (ADCC), so as to reduce reliance on intact immunologic systems in the patient and effector mechanism-related toxicity. In vitro studies show that replacing the Fc region of hL243γ1, a humanized IgG1 anti-HLA-DR mAb, with the IgG4 isotype abrogates the effector cell functions of the antibody (ADCC and CDC) while retaining its antigen-binding properties, antiproliferative capacity (in vitro and in vivo), and the ability to induce apoptosis concurrent with activation of the AKT survival pathway. Growth inhibition was evaluated compared with and in combination with the anti-CD20 mAb rituximab, with the combination being more effective than rituximab alone in inhibiting proliferation. Thus, hL243γ4P is indistinguishable from hL243γ1 and the parental murine mAb in assays dependent on antigen recognition. The abrogation of ADCC and CDC, which are believed to play a major role in side effects of mAb therapy, may make this antibody an attractive clinical agent. In addition, combination of hL243γ4P with rituximab offers the prospect for improved patient outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|